Prioritizing Therapeutics for Lung Cancer: An Integrative Meta-analysis of Cancer Gene Signatures and Chemogenomic Data
Fig 4
Prioritizing drug candidates with GI50 values and chemical structures.
Twenty-three of the significant drugs inhibit growth in a majority of lung cancer cell lines (top). A further 11 significant drugs not tested in NCI-60 are highly structurally similar (Tanimoto similarity > = 0.8) to one or more of the sixteen (bottom).